Emicizumab, the first of these non‐factor therapies to be licensed for inhibitor patients, is a bispecific antibody that binds to both factor IXa and factor X and in doing so supports conformational changes that allows factor IXa to activate FX in the absence of FVIII.35 The efficacy of emicizumab in preventing bleeds has been demonstrated to be much higher than that of traditional bypassing agents.13 On the basis of this, emicizumab was approved in November 2017 by the FDA and in February 2018 by the EMA for prophylactic use in adults and children with haemophilia A and inhibitors to FVIII. This evidence concerns the gene F10 and hemophilia A.